Laura R Lander1, Vincent Setola2, Shane W Kaski3, Stephan Brooks4, Sijin Wen5, Marc W Haut6, David P Siderovski3, James H Berry7. 1. West Virginia University School of Medicine, Morgantown, WV. 2. Departments of Behavioral Medicine & Psychiatry, Neuroscience, and Physiology & Pharmacology, West Virginia University School of Medicine, Morgantown, WV. 3. Department of Physiology & Pharmacology, West Virginia University School of Medicine, Morgantown, WV. 4. Clarion University of Pennsylvania, Clarion, PA. 5. Department of Biostatistics, West Virginia University School of Public Health, Morgantown, WV. 6. Department of Behavioral Medicine & Psychiatry, West Virginia University School of Medicine, Morgantown, WV. 7. Chestnut Ridge Center and Inpatient Acute Dual Diagnosis Program, West Virginia University School of Medicine, Morgantown, WV.
Abstract
OBJECTIVE: Pilot study to assess utility in opioid use disorder (OUD) of a panel of single nucleotide polymorphisms in genes previously related to substance use disorder (SUD) and/or phenotypes that predispose individuals to OUD/SUD. DESIGN: Genetic association study. SETTING: West Virginia University's Chestnut Ridge Center Comprehensive Opioid Abuse Treatment (COAT) clinic for individuals diagnosed with OUD. PATIENTS: Sixty patients 18 years of age or older with OUD undergoing medication (buprenorphine/naloxone)-assisted treatment (MAT); all sixty patients recruited contributed samples for genetic analysis. OUTCOME MEASURES: Minor allele frequencies for single nucleotide polymorphisms. RESULTS: Four of the fourteen single nucleotide polymorphisms examined were present at frequencies that are statistically significantly different than in a demographically-matched general population. CONCLUSIONS: For the purposes of testing WV individuals via genetic means for predisposition to OUD, at least four single nucleotide polymorphisms in three genes are likely to have utility in predicting susceptibility. Additional studies with larger populations will need to be conducted to confirm these results before use in a clinical setting.
OBJECTIVE: Pilot study to assess utility in opioid use disorder (OUD) of a panel of single nucleotide polymorphisms in genes previously related to substance use disorder (SUD) and/or phenotypes that predispose individuals to OUD/SUD. DESIGN: Genetic association study. SETTING: West Virginia University's Chestnut Ridge Center Comprehensive Opioid Abuse Treatment (COAT) clinic for individuals diagnosed with OUD. PATIENTS: Sixty patients 18 years of age or older with OUD undergoing medication (buprenorphine/naloxone)-assisted treatment (MAT); all sixty patients recruited contributed samples for genetic analysis. OUTCOME MEASURES: Minor allele frequencies for single nucleotide polymorphisms. RESULTS: Four of the fourteen single nucleotide polymorphisms examined were present at frequencies that are statistically significantly different than in a demographically-matched general population. CONCLUSIONS: For the purposes of testing WV individuals via genetic means for predisposition to OUD, at least four single nucleotide polymorphisms in three genes are likely to have utility in predicting susceptibility. Additional studies with larger populations will need to be conducted to confirm these results before use in a clinical setting.
Entities:
Keywords:
Opioid use disorder (OUD); genetic testing; single nucleotide polymorphisms (SNPs); substance use disorder (SUD)
Authors: A J Oliveira-Dos-Santos; G Matsumoto; B E Snow; D Bai; F P Houston; I Q Whishaw; S Mariathasan; T Sasaki; A Wakeham; P S Ohashi; J C Roder; C A Barnes; D P Siderovski; J M Penninger Journal: Proc Natl Acad Sci U S A Date: 2000-10-24 Impact factor: 11.205
Authors: Michael F Egan; Masami Kojima; Joseph H Callicott; Terry E Goldberg; Bhaskar S Kolachana; Alessandro Bertolino; Eugene Zaitsev; Bert Gold; David Goldman; Michael Dean; Bai Lu; Daniel R Weinberger Journal: Cell Date: 2003-01-24 Impact factor: 41.582
Authors: Jordan W Smoller; Martin P Paulus; Jesen A Fagerness; Shaun Purcell; Lesley H Yamaki; Dina Hirshfeld-Becker; Joseph Biederman; Jerrold F Rosenbaum; Joel Gelernter; Murray B Stein Journal: Arch Gen Psychiatry Date: 2008-03
Authors: R de Cid; F Fonseca; M Gratacòs; F Gutierrez; R Martín-Santos; X Estivill; M Torrens Journal: Genes Brain Behav Date: 2008-07 Impact factor: 3.449
Authors: Joshua D Gross; Shane W Kaski; Karl T Schmidt; Elizabeth S Cogan; Kristen M Boyt; Kim Wix; Adam B Schroer; Zoe A McElligott; David P Siderovski; Vincent Setola Journal: Neuropsychopharmacology Date: 2019-05-29 Impact factor: 7.853